Patients suffering from chronic myeloid leukemia (CML)-- a rare form of cancer -- can get huge financial benefits if they start using the generic form of drug Gleevec the patent of which expired in January this year a study said. If we start all patients on the generic form of Gleevec and it works then they are on a generic for the rest of their lives said lead author William V. Padula an assistant professor at the Johns Hopkins University. This amounts to a huge cost savings for them and their insurers he added. The study published recently in the